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Abstract 10 
 An effort to prevent PJI has led to the development of antimicrobial dressings that 11 
support wound healing. We sought to determine whether Aquacel Surgical dressing 12 
independently reduces the rate of acute PJI following TJA. A single institution retrospective 13 
chart review of 903 consecutive cases who received the Aquacel Surgical dressing and 875 14 
consecutive cases who received standard gauze dressing was conducted to determine the 15 
incidence of acute PJI (within 3 months). The incidence of acute PJI is 0.44% in the Aquacel 16 
dressing group compared to 1.7% in the standard gauze dressing group (P = 0.005). Multivariate 17 
analysis revealed that use of Aquacel dressing was an independent risk factor for reduction of PJI 18 
(odds ratio of 0.165, 95% conﬁdence interval: 0.051–0.533). Aquacel Surgical dressing 19 
signiﬁcantly reduces the incidence of acute PJI. 20 
21 
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Introduction 22 
 Periprosthetic joint infection (PJI) is one of the most dreaded complications that occur 23 
after total joint arthroplasty (TJA). PJI is reported to occur in 1%–4% and 0.59%–2%of patients 24 
who have undergone total knee and hip arthroplasty, respectively [1,2]. The infection causes 25 
physical, emotional, and ﬁnancial strain to patients and their families as well as an immense 26 
monetary burden to hospitals and our economy. The annual nationwide cost to control infection 27 
is approximately $250 million. The cost of treating an individual PJI can be in excess of $50,000 28 
and if the offending organism is antibiotic resistant, i.e. MRSA, that cost can surpass $100,000 29 
[3,4]. Additionally, perioperative mortality associated with PJI can be 10 times greater than with 30 
primary TJA [5,6]. 31 
 Eradication of infection often requires additional surgery and is distressful for both the 32 
treating physician and patient. While there are numerous possible causes for PJI, a few important 33 
risk factors related to the wound itself have been identiﬁed including wound drainage and 34 
superﬁcial wound infections [7]. The traditional approach to wound care consists of a simple 35 
dressing that could be removed after 1 or 2 days with the idea that the wound re-epithelializes 36 
during that time and can then be left uncovered.[8]. Among efforts to prevent the occurrence of 37 
PJI, commercial dressings have been developed to optimize wound healing, seal wound drainage 38 
and have antimicrobial properties [9]. In contrast to the conventional use of standard gauze 39 
bandages, these dressings feature antimicrobial linings and have shown to decrease surgical site 40 
infection rates [10]. 41 
 The Aquacel Ag Hydroﬁber dressing is an antimicrobial dressing that consists of a 42 
weaved cellulose center that contours to the skin to eliminate dead space, absorbs exudates, 43 
releases ionic silver to reduce microbial activity and supports wound healing [11]. Furthermore, 44 
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the dressing seals the wound and prevents seepage of drainage beyond the dressing perimeter.  45 
The objective of this study was to evaluate the effect of using this dressing on the occurrence of 46 
acute PJI in patients undergoing TJA. We hypothesized that the Aquacel Ag Hydroﬁber dressing 47 
would support healing following surgery and possibly reduce the rate of acute PJI.  48 
 49 
Methods 50 
 Prior to initiation of the study, institutional review board approval was obtained. Using 51 
our computerized joint arthroplasty database, 950 consecutive patients who underwent primary 52 
total hip or total knee arthroplasty between October 2010 and March 2012 and received the 53 
Aquacel dressing were identiﬁed. A list of 950 consecutive patients who received standard 54 
dressings and who were admitted to the hospital before implementing systematic use of the 55 
Aquacel dressing from April 2007 to August 2010 was generated in a similar fashion. To allow 56 
for consistency in the use of the new dressing, data from the initial 6 weeks when Aquacel 57 
dressing was utilized were omitted. Exclusion criteria included hip hemiarthroplasty, 58 
unicompartmental knee arthroplasty, TJA for fracture treatment, conversion TJA, and revision 59 
TJA. Each case was reviewed to verify the exclusion criteria and collect demographic 60 
information, medical comorbidities, intraoperative parameters and development of acute PJI. The 61 
latter was defined as PJI occurring within 3 months of surgery based on the new definition 62 
criteria established by the Musculoskeletal Infection Society [12]. After eliminating patients 63 
based on the exclusion criteria, 903 patients with hip (392), knee (508) or hip and knee (3) 64 
arthroplasties were retained in the Aquacel group and 875 patients with hip (376) or knee (499) 65 
arthroplasty in the standard dressing group. The Aquacel dressing was applied on the surgical 66 
site in sterile conditions in the operating room and kept in place for 5 days postoperatively. 67 
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Standard dressing application consisted of sterile xeroform and gauze applied over the incision 68 
site in the operating room and wrapped in an ace bandage that remained in place for 2 days 69 
postoperatively. 70 
 In addition to the application of the Aquacel Surgical dressing, changes in clinical 71 
practice during the study period included the use of dual intravenous antibiotic prophylaxis with 72 
vancomycin and cefazolin (vs. cefazolin alone previously) and systematic irrigation with dilute 73 
betadine before wound closure. These changes occurred 9 and 4 months before the end of the 74 
study period respectively. A total of 37 patient-related and procedure-related risk factors were 75 
taken into account in a multivariate analysis model where the dependent variable was the 76 
development of acute PJI (Table 1). Statistical analyses were performed using R version 2.15.1 77 
(R Foundation for Statistical Computing, Vienna, Austria). 78 
 79 
Results 80 
 The prevalence of acute PJI was lower in the Aquacel group (0.44%) compared to the 81 
standard dressing group (1.71%). Bivariate analysis conducted with Fisher's test first showed this 82 
to be statistically significant (P = 0.005). A backward stepwise logistic regression model retained 83 
7 independent risk factors for PJI (of 37 variables), including the use of Aquacel dressing, with 84 
an independent odds ratio of 0.165 (95% confidence interval: 0.051–0.533). Other independent 85 
significant risk factors for infection were as follows: older age, higher body mass index, smoking 86 
status, thyroid disease, liver disease and history of steroid treatment (Table 2). Notably, 87 
utilization of vancomycin prophylaxis and betadine irrigation were not shown to be significant 88 
independent protective factors for acute PJI. 89 
 90 
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Discussion 91 
 PJI is a major healthcare concern with mental, physical and financial burden on affected 92 
patients. With projected exponential increases in its incidence and costs, and the predicted 93 
reforms of healthcare reimbursement, prevention of this complication is gaining more 94 
importance [13]. Wound healing problems and superficial surgical site infections have 95 
consistently shown to be determining risk factors for the development of PJI [14,15]. Thus, 96 
addressing these specific issues may prevent the occurrence of deep infection. The Aquacel 97 
dressing has several features that could positively affect the wound environment: it sequesters 98 
fluid to avoid tissue maceration, while at the same time releasing a gel that maintains a relatively 99 
humid environment; it is also completely impermeable, preventing bacteria from entering the 100 
wound site from the outside environment and maintaining hypoxia in the wound, which has been 101 
shown to enhance healing and cellular immunity through the up-regulation of hypoxic-inducible 102 
factors [16]. The addition of silver provides antimicrobial activity [17]. 103 
 The use of the Aquacel dressing in TJA has previously been shown to create less need for 104 
dressing changes, thus decreasing burden on healthcare personnel, diminishing superficial wound 105 
problem, and avoiding delays in hospital discharge due to wound healing issues [18]. As the first 106 
study to correlate Aquacel dressing with acute PJI, our results show that this dressing is an 107 
effective measure to significantly reduce the occurrence of acute PJI after TJA, when compared 108 
to standard dressings with gauze and tape. In our series, it independently reduced the rate of 109 
acute PJI approximately sixfold. 110 
 The cost of one standard Aquacel dressing at our institution is $39.05. The cost to treat a 111 
PJI has been variably estimated to range from $50,000 to over $100,000 [13]. A standard taped 112 
surgical gauze dressing costs approximately $5.00. Therefore, the additional cost per case for an 113 
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Aquacel dressing is about $34.00. Infection after TJA has been reported to have an incidence 114 
ranging from 1.0% to 2.0% [4]. In the United States., there are over 1,000,000 TKAs and THAs 115 
performed annually [19]. Assuming the lowest cost ($50,000) of PJI treatment and the lower 116 
incidence (1%) of reported PJI, the annual costs to manage PJI in the United States likely exceed 117 
$500,000,000. The cost of using an Aquacel dressing routinely in the United States after TJA 118 
would add approximately $27,000,000 in cost. If the reported fourfold reduction in PJI noted in 119 
our study is accurate, the cost of PJI management in the United States could be reduced by at 120 
approximately $375,000,000 with use of an Aquacel dressing. Therefore, the additional cost 121 
associated with routine use of the Aquacel dressing after TJA can be readily justified. 122 
 We recognize several limitations to our study, such as, principally, its retrospective 123 
design on a cohort of consecutive patients.  Nonetheless, we were able to include a relatively 124 
large number of subjects and all changes in practice, as well as potential confounding factors, 125 
were taken into account in a multivariate model to ascertain the independent protective effect of 126 
the Aquacel dressing. Our main concern was the confounding effect of intravenous vancomycin 127 
prophylaxis and dilute betadine irrigation, two practices we implemented based on recent 128 
supportive evidence in the literature [20,21].  However, these two factors did not reach a 129 
significant effect on the development of PJI in our current study. This lack of significance is 130 
possibly due to the limited number of subjects involved since these two practices were 131 
introduced at our institution relatively late in the study period. Finally, our main outcome 132 
measurement consisted of PJI occurring within 3 months of surgery. We elected to use the 3-133 
month minimum follow-up, in compliance with the recent recommendations of the Center for 134 
Disease Control and Prevention, which uses this period to determine if an infection occurring 135 
after surgery could be directly attributed to that procedure or not [22]. 136 
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 Despite the aforementioned limitations, this case-controlled study demonstrated that the 137 
Aquacel Ag Surgical wound dressing with ionic silver significantly reduced the incidence of 138 
acute PJI in our cohort of patients. Its systematic use suggests that it would be an effective 139 
measure to prevent the occurrence of acute PJI following TJA and thus diminish the significant 140 
healthcare costs and patient morbidity of PJI. 141 
142 
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Table 1 - List of patient-related and procedure-related factors included in the first step of the 224 
logistic regression model 225 
 226 
Demographic factors 
Age 
Gender 
BMI 
Procedure-related factors 
 
Joint 
Bilateral procedure 
OR time 
Transfusion need 
Type of anesthesia 
Length of stay 
Aquacel dressing 
Dilute betadine irrigation 
Comorbidities 
 
Smoking status 
Frequent alcohol drinking 
History of MI 
Congestive heart failure 
Peripheral vascular disease 
Cerebro-vascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Coronary artery disease 
Peptic ulcer disease 
Liver disease 
Diabetes mellitus 
Chronic renal disease 
Malignancy (history, active  
disease or metastatic disease) 
Rheumatoid disease 
Hypertension 
Dyslipidemia 
Thyroid disease 
Psychiatric disease 
Anemia 
Dysrythmia 
History of DVT or PE 
GERD 
History of steroid treatment 
ASA 
 227 
ASA = American Society of Anaesthesiologistsphysical status classi-cation, BMI= Body Mass 228 
Index, DVT = Deep VeinThrombosis, GERD = Gastro-EsophagealReux Disease, MI = 229 
Myocardial Infarction,OR = Operating Room, PE = PulmonaryEmbolism. 230 
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Table 2 - Table 2. Factors included in the final logisticregression model with independent 
oddsratios and 95% confidence intervals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 231 
 
Odds Ratio 
(95% confidence interval) 
p-value 
Aquacel® dressing use  0.17 (0.05 – 0.53) 0.003 
Age  1.09 (1.03 – 1.14) 0.002 
Body mass index 1.10 (1.03 - 1.19) 0.006 
Former Smoker  3.02 (1.12-8.12) 0.029 
Thyroid disease  3.71 (1.42 – 9.67) 0.007 
Liver disease  7.03 (1.43-34.60) 0.017 
History of systemic steroid treatment  22.22 (1.83 – 269.45) 0.015 
